This is single in kind in a series...

This is single in kind in a series excerpted from the Recommendations and Rationale Statements released through the current U.S. Preventive Services Task Force (USPSTF). These statements address preventive health services for use in primary-care clinical settings, including screening criterions counseling, and chemoprevention. The integral statement is available in HTML and PDF formats within the AFP Web site at www.aafp. org/afp/20030515/us. html This statement is part of AFP's CME diocese "Clinical Quiz" on page 2061

This statement summarizes the passing from hand to hand U.S. Preventive Services Task Force (USPSTF) recommendations forward screening for type 2 diabetes in adults and the supporting scientific evidence. They update the 1996 recommendations contained in the Guide to Clinical Preventive Services, next to the first edition. (1) Explanations of the ratings and of the solidity of overall evidence are given in Tables 1 and 2 respectively. The consummated information on which this statement is based, including evidence tables and respects is available in the summary of the evidence (2) and the systematic evidence review (3) forward this topic, which is available forward the USPSTF Web site (www.preventiveservices.ahrq.gov) and from one side the National Guideline Clearinghouse (www.guideline.gov). The summary of the evidence and the recommendation statement are also available in print between the walls of the Agency for Healthcare Research and Quality Publications Clearinghouse (800-358-9295; e-mail: ahrqpubs@ahrq.gov).

Summary of Recommendations

* The USPSTF judges that the evidence is insufficient to approve for or against routinely screening asymptomatic adults for stamp 2 diabetes, impaired glucose tolerance, or impaired fasting grape-sugar I recommendation.

The USPSTF rest good evidence that available screening exhibitions can accurately detect type 2 diabetes during an early, asymptomatic phase. The USPSTF also raise good evidence that intensive glycemic curb in patients with clinically discovered (not screening detected) diabetes can mould the progression of microvascular disease. However, the benefits of tight glycemic direct on microvascular clinical outcomes take years to become apparent. It has not been demonstrated that beginning diabetes direct early as a result of screening provides an incremental benefit compared with initiating treatment after clinical diagnosis. Existing studies have not shown that tight glycemic superintend significantly reduces macrovascular complications, including myocardial infarction and knock The USPSTF found poor evidence to assess possible harms of screening. As a conclusion the USPSTF could not determine the balance of benefits and harms of routine screening for sign 2 diabetes.

* The USPSTF commends screening for type 2 diabetes in adults with hypertension or hyperlipidemia. B recommendation.

The USPSTF rest good evidence that, in adults who have hypertension and clinically discovered diabetes, lowering blood pressure below conventional target kin pressure values reduces the incidence of cardiovascular adventures and cardiovascular mortality; this evidence is considered fair when extrapolated to cases of diabetes bring to lighted by screening. Among patients with hyperlipidemia, there is worthy evidence that detecting diabetes substantially improves estimates of individual risk for coronary heart disease, which is an integral part of decisions about lipid-lowering therapy.

Clinical Considerations

* In the absence of evidence of direct benefits of routine screening for adumbration 2 diabetes, the decision to shield individual patients is a matter of clinical notion Patients at increased risk for cardiovascular disease may benefit mostly from screening for type 2 diabetes, since management of cardiovascular risk factors leads to reductions in major cardiovascular occurrences Clinicians should assist patients in making that choice. In addition, clinicians should be alert to symptoms suggestive of diabetes (i.e., polydipsia, polyuria) and trial anyone with these symptoms.

* Screening for diabetes in patients with hypertension or hyperlipidemia should be part of an integrated approach to abate cardiovascular risk. Lower targets for children pressure (i.e., diastolic blood compressing [less than or equal to]80 mm Hg) are beneficial for patients with diabetes and high line pressure. The report of the Adult Treatment Panel III of the National Cholesterol Education Program make acceptables lower targets for low-density lipoprotein cholesterol for patients with diabetes. Attention to other risk factors, like as physical inactivity, diet, and overweight, is also important to decrease risk for heart disease and to improve starch-sugar control.

* Three ordeals have been used to cloak for diabetes: fasting plasma starch-sugar (FPG), two-hour post-load plasma starch-sugar (2-hr PG), and glycosylated hemoglobin [A.sub.1c] (Hb[A.sub.1c]). The American Diabetes Association (ADA) has commited the FPG test ([greater than or equal to]126 mg by means of dL [7 mmol per L]) for screening because it is easier and faster to perform, more convenient and acceptable to patients, and les expensive than other screening touchstones The FPG test is more reproducible than the 2-hr PG criterion has less intraindividual variation, and has similar predictive value for progress to maturity of microvascular complications of diabetes. Compared with the FPG standard the 2-hr PG test may lead to more individuals being diagnosed as diabetic. Hb[A.sub.1c] is more closely related to FPG than to 2-hr PG unless at the usual cut-points it is les sensitive in detecting lower on a levels of hyperglycemia. The random capillary house glucose (CBG) test has been shown to have reasonable sensitivity (75 percent at a cut-point of [greater than or equal to]120 mg by dL) in detecting persons who have either an FPG plain [greater than or equal to]126 mg for dL or a 2-hr PG plain [greater than or equal to]200 mg through dL, if results are interpreted according to age and time since last meal; however, the random family glucose test is less well standardized for screening for diabetes.